Vertex demonstrates a methodical approach to building its post-cystic fibrosis pipeline. Under its current CEO, the company started with sub-$1 billion deals to "get their feet wet" before escalating to larger acquisitions like the $4.9B Alpine deal and now the $10B Crenetics deal, indicating a carefully managed increase in scale and risk.

The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

Major pharmaceutical companies are committing to bio-buck deals worth billions for unproven, preclinical assets. The Sanofi-Irindale deal ($2.56B potential) and the Pfizer-Cartography deal ($850M+ potential) for discovery-stage programs show a high appetite for risk when accessing innovative technology platforms and novel targets early on.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

After a major internal scientific setback in the obesity space, Pfizer acquired a company with a promising drug. This strategy wasn't just about buying a product, but acquiring a missing scientific asset to plug into its existing world-class commercial and manufacturing infrastructure, thereby capitalizing on its established strengths.

Major firms like Merck employ varied deal structures to build pipelines. Merck's $6.7 billion all-upfront acquisition of Terns for a Phase 1-2 asset contrasts with its Quotient collaboration, which has a small $20 million upfront but $2.2 billion in discovery-stage milestones. This highlights a flexible approach to risk and reward.

Neurocrine's move from neuroscience into obesity is not a random leap but a calculated pivot. The company is leveraging its deep, historical expertise in the CRF biological system, a shared mechanism between the fields, to de-risk its entry into a new, high-growth therapeutic area.

The M&A landscape is evolving as a new tier of large, but not Big Pharma-sized, biotechs are now executing their own billion-dollar acquisitions. Companies like Neurocrine, BioMarin, and Genmab are creating a new class of strategic buyers, diversifying exit opportunities for smaller biotech firms.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.